

A Dkt pp01617.002 2300-1617 PATENT 3-10-91

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington,

D.C. 20231 on

Date

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFIC

In Re Application of:

COIT et al.

Serial No.: 09/721,479

Group Art Unit: Unassigned

Filing Date: November 22, 2000

Examiner: Unassigned

1648

Title: NOVEL HCV NON-STRUCTURAL POLYPEPTIDE

TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith for filing is an Information Disclosure Statement, including a Form PTO-1449 and copies of the cited references. It is believed that no fee is due.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: Rb 28, 2001

By:

Dahna S. Pasternak Registration No. 41,411

Attorney for Applicants

CHIRON CORPORATION
Intellectual Property - R440

P.O. Box 8097

Emeryville, CA 94662-8097 Telephone: 650-325-7812

Facsimile: 650-325-7823





I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington

D.C. 20231 on

Date O

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

COIT et al.

Serial No.: 09/721,479

Group Art Unit: Unassigned

Filing Date: November 22, 2000

Examiner: Unassigned

Title: NOVEL HCV NON-STRUCTURAL POLYPEPTIDE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The information listed below may be material to the examination of the above-identified application. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of official record in the application. The information includes:

Botarelli et al., "T-Lymphocyte Response to Hepatitis C Virus in Different Clinical Courses of Infection," *Gastroenterology* 104:580-587 (1993);

Cooper et al., "Analysis of a Successful Immune Response Against Hepatitis C Virus," *Immunity* 10:439-449 (1999);

Diepolder et al., "Possible Mechanism Involving T-lymphocyte Response to Non-structural Protein 3 in Viral Clearance in Acute Hepatitis C Virus Infection," *Lancet* 346:1006-1007(1995);

Diepolder et al., "Immunodominant CD4" T-Cell Epitope Within Nonstructural Protein 3 in Acute Hepatitis C Virus Infection," *Journal of Virology* 71:6011-6019 (1997);

Farrari et al., "T-Cell Response to Structural and Nonstructural Hepatitis C Virus Antigens in Persistent and Self-Limited Hepatitis C Virus Infections," *Hepatology* 19:286-295 (1994);



Atty Dkt PP01617.002 USSN: 09/721,479

PATENT

Hoffman et al., "Mapping of Immunodominant CD4^{*} T Lymphocyte Epitiopes of Hepatitis C Virus Antigens and Their Relevance During the Course of Chronic Infection," *Hepatology* 21:632-638 (1995);

Iwata et al., "Interferon Gamma Production by Peripheral Blood Lymphocytes to Hepatitis C Virus Core Protein in Chronic Hepatitis C Infection," *Hepatology* 22:1057-1064 (1995);

Minutello et al., "Compartmentalization of T Lymphocytes to the Site of Disease: Intrahepatic CD4⁺ T Cells Specific for the Protein NS4 of Hepatitis C Virus in Patients with Chronic Hepatitis C," *J. Exp. Med.* 178:17-25 (1993);

Missale et al., "Different Clinical Behaviors of Acute Hepatitis C Virus Infection are Associated with Different Vigor of the Anti-viral Cell-mediated Immune Response," *J. Clin. Invest.* 98:706-714 (1996);

Tsai et al., "Detection of Type 2-Like T-Helper Cells in Hepatitis C Virus Infection: Implications for Hepatitis C Virus Chronicity," *Hepatology* <u>25</u>:449-458 (1997); and

Tsai et al., "Cellular Immune Responses in Patients With Dual Infection of Hepatitis B and C Viruses: Dominant Role of Hepatitis C Virus," *Hepatology* 21:908-912 (1995).

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

Date: Feb 28, 2001

By: Dahna S. Pasternak

Registration No. 41,411 Attorney for Applicants

CHIRON CORPORATION Intellectual Property - R440 P.O. Box 8097

Emeryville, CA 94662-8097 Telephone: 650-325-7812 Facsimile: 650-325-7823